First identified as a drug candidate for clinical trials by world-renowned investigators at UBC, FS2 demonstrated during pre-clinical trials that it is the first drug to successfully target scarring on the molecular level. That means it essentially stops scarring that results from the body over-repairing after an injury, surgery or disease, and it does so at the inception of both external and internal scarring. What is significant about this result is that, to date, there has been no therapeutic agent approved by the FDA, Health Canada, or any other international regulatory agency to target the molecular aspects of scarring. Nevertheless, there are a plethora of costly cosmetic treatments on the market today that show little – if any — efficacy in the treatment of scarring. Meanwhile, the medical alternatives are costly, painful and focused on healing wounds, not on preventing and eliminating scars.